Livforsakringsbolaget Skandia Omsesidigt Purchases Shares of 6,500 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 4th quarter, Holdings Channel reports. The firm purchased 6,500 shares of the company’s stock, valued at approximately $210,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Harmony Biosciences by 95.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,533 shares of the company’s stock valued at $50,000 after buying an additional 748 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Harmony Biosciences during the 2nd quarter worth about $61,000. State of Wyoming grew its holdings in shares of Harmony Biosciences by 91.6% during the 4th quarter. State of Wyoming now owns 1,462 shares of the company’s stock worth $81,000 after purchasing an additional 699 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Harmony Biosciences by 290.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,571 shares of the company’s stock worth $84,000 after purchasing an additional 1,913 shares during the period. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Harmony Biosciences by 38.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,724 shares of the company’s stock worth $96,000 after purchasing an additional 757 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HRMY shares. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 9th. Bank of America reiterated an “underperform” rating and set a $30.00 target price on shares of Harmony Biosciences in a report on Tuesday, January 2nd. Mizuho reduced their price target on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $49.00 price target on shares of Harmony Biosciences in a report on Friday, April 12th. Finally, The Goldman Sachs Group lifted their price objective on shares of Harmony Biosciences from $25.00 to $28.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.63.

Insider Activity

In other news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 28.40% of the company’s stock.

Harmony Biosciences Stock Down 0.2 %

Harmony Biosciences stock traded down $0.07 during midday trading on Thursday, hitting $29.12. The stock had a trading volume of 5,269 shares, compared to its average volume of 369,236. The company has a current ratio of 2.75, a quick ratio of 2.72 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1.65 billion, a P/E ratio of 13.77, a P/E/G ratio of 0.42 and a beta of 0.73. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The business has a fifty day moving average price of $32.03 and a 200 day moving average price of $30.12.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Thursday, February 22nd. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.29). The company had revenue of $168.40 million for the quarter, compared to the consensus estimate of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The firm’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period last year, the company posted $1.01 earnings per share. Research analysts predict that Harmony Biosciences Holdings, Inc. will post 3 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.